International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs 2021
Related Enduring Materials
Enduring Materials
Day 1 - Monday, 20 September 2021
Day 2 - Tuesday, 21 September 2021
Day 3 - Wednesday, 22 September 2021
In Memoriam: Dr. Charles Boucher
We are deeply saddened to share that Dr. Charles Boucher, a member of the Academic Advisory Board of the International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs 2021, has passed away after a courageous battle with cancer. Read our full memorial >
In Memoriam: Dr. John Gerber
We are deeply saddened to hear that Dr. John Gerber has passed away. Dr. Gerber was an integral faculty member of the early Intl. Workshop on Clinical Pharmacology of HIV Drugs programs, which is now in its 22nd edition. His contributions to this program and the pharmacology field are tremendous and he will be missed.
Welcome
Understanding the clinical pharmacology of antiviral therapy is pivotal to designing optimal treatment and prevention strategies. The International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs gathers leading experts to discuss all aspects of the optimal use of antiviral therapy including drug-drug interactions, pharmacokinetics of investigational and existing drugs, pharmacodynamics, drug dosing in special populations, post-marketing surveillance, and regulatory considerations.
Program Chairs 2021
General Information
We are available to answer any questions or concerns that you may have about your participation at the International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2021. For more information, please contact Ulrike Bilgram via ulrike@amededu.com.
To stay updated on developments about this workshop, make sure that you are signed up for our newsletter.
The workshop provided a platform for discussions on current topics fundamental to the optimal use of antiviral therapy including drug-drug interactions, pharmacokinetics of investigational agents and existing drugs, pharmacodynamics, drug dosing in special populations, postmarketing surveillance, and regulatory considerations.
- Pharmacists;
- Clinicians/ researchers;
- Industry representatives;
- Regulatory scientists;
- Government representatives;
- Post-graduate students; and
- Others involved in the clinical pharmacology of antiviral therapy.
- Gather experts involved in clinical pharmacology from different disciplines in an interactive workshop setting;
- Provide a platform for presentation and discussion of the latest developments in the field;
- Share information on ongoing pharmacological studies;
- Translate new data to treatment guidelines; and
- Stimulate discussion and consensus on best practices.
- Outline new developments in antiviral therapy;
- Identify treatment options for hepatitis-infected patients;
- Reflect on the role of pharmacogenomics in clinical management; and
- Describe the various pharmacological parameters of integrase inhibitors.
Practical Information
Translation will not be provided.
Organizing Committee
The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.
Scientific Committee
The members of Scientific Committee are hand-picked by the Organizing Committee and the conference secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.
- Peter Anderson, PharmD - University of Colorado Denver, United States
- Tim Cressey, PhD - Chiang Mai University, Thailand
- Rodolphe Garraffo, MD - Hopital Pasteur Nice, France
- David Haas, MD - Vanderbilt University Medical Ctr, United States
- Saye Khoo, MD - University of Liverpool, United Kingdom
- Michael Kurowski, MD - Auguste-Victoria Hospital, Jerusalem
- Mohammed Lamorde, MD - Infectious Diseases Institute, Uganda
- Lawrence Lee, MBBS, PhD - National University of Singapore, Singapore
- Gilles Peytavin, PharmD, PhD - Bichat-Cl. Bernard Hospital, France
- Kellie Schoolar-Reynolds, PharmD - Food and Drug Administration, United States
- Kimberly Struble, PharmD - Food and Drug Administration, United States
- Stephen Taylor, MRCP, PhD - Birmingham Heartlands Hospital, United Kingdom
Academic Advisory Board
The members of the Academic Advisory Board (AAB) are former members of the OC and remain active the in planning of the program for the next year. Members of the current OC are selected from this group.
- David Back, PhD - University of Liverpool, United Kingdom
- Terrence Blaschke, MD - Stanford University School of Medicine, United States
- † Charles Boucher, PhD - Erasmus Medical Center, the Netherlands
- David Burger, MD, PhD - Radboud University Medical Center, the Netherlands
- Giovanni Di Perri, MD, PhD - University of Torino, Italy
- Courtney Fletcher, PharmD - University of Nebraska Medical Center, United States
- Charles Flexner, MD - Johns Hopkins University, United States
- Angela Kashuba, PharmD - University of North Carolina at Chapel Hill, United States
- Jürgen Rockstroh, MD - University of Bonn, Germany
- Jonathan Schapiro, MD - Sheba Medical Centre, Israel
Industry Liaison Board
The Industry Liaison Board, consisting of leading medical scientists of the pharmaceutical industry, is asked to give input and suggestions that help the Organizing Committee in planning the workshop and providing support on topics of interest and innovative suggestions to optimize audience participation. The Industry Liaison Board assists the Organizing Committee by suggesting the most current and critical topics to bring the audience up-to-date on the most current research in the pharmaceutical industry in related disciplines.
- Timonthy Eley - Arbutus
- Yash Gandhi - BMS
- Daria Hazuda - Merck
- Thomas Kakuda - Alios BioPharma
- Charles LaPorte - Janssen Biologics
- Wei Liu - AbbVie
- Anita Mathias - Gilead Sciences
- Parul Patel - ViiV Healthcare
- Manoli Vourvahis - Pfizer
Support Our Initiative
Financial backing helps us deliver an impactful meeting experience for the benefit of healthcare professionals, researchers, and community representatives involved in Clinical Pharmacology of HIV, Hepatitis, and other Antiviral Drugs.
This collaboration plays a vital role in both the organizational as well as scientific success of the program.
To show your commitment to the cause and get in touch with us for a tailored support package, please contact Ms. Goda Adomonis at goda.adomonis@amededu.com or call +31 6 23711504.
Benefits of Support
By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.
- Symposium opportunities
- Non-commercial interviews with company representatives
- Verbal acknowledgment during the program
- Discounted and complimentary registrations for your representatives
- Company acknowledgment on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
- Company acknowledgment on printed meeting materials including but not limited to banners and the program book
- Digital and printed advertising opportunities
- Social media shout-outs
- Logo on the conference bag
*Subject to the support level
